140 related articles for article (PubMed ID: 26354504)
1. In vitro and in vivo evaluation of cucurbitacin E on rat hepatic CYP2C11 expression and activity using LC-MS/MS.
Lu J; Ding T; Qin X; Liu M; Wang X
Sci China Life Sci; 2017 Feb; 60(2):215-224. PubMed ID: 26354504
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat.
Wang X; Lee WY; Or PM; Yeung JH
Phytomedicine; 2010 Mar; 17(3-4):203-11. PubMed ID: 19679455
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of tolbutamide and its metabolite 4-hydroxy tolbutamide in poloxamer 407-induced hyperlipidemic rats.
Choi MR; Kwon MH; Cho YY; Choi HD; Kim YC; Kang HE
Biopharm Drug Dispos; 2014 Jul; 35(5):264-74. PubMed ID: 24590592
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the impact of 16-dehydropregnenolone on the activity and expression of rat hepatic cytochrome P450 enzymes.
Ramakrishna R; Bhateria M; Singh R; Bhatta RS
J Steroid Biochem Mol Biol; 2016 Oct; 163():183-92. PubMed ID: 27224941
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interference of doxorubicin with tolbutamide due to reduced metabolic clearance with increased serum unbound fraction in rats.
Fukuno S; Nagai K; Yamamoto K; Tanimura T; Nabe T; Konishi H
Biopharm Drug Dispos; 2019 Jul; 40(7):225-233. PubMed ID: 31215040
[TBL] [Abstract][Full Text] [Related]
6. Altered tolbutamide pharmacokinetics by a decrease in hepatic expression of CYP2C6/11 in rats pretreated with 5-fluorouracil.
Fukuno S; Nagai K; Kasahara K; Mizobata Y; Omotani S; Hatsuda Y; Myotoku M; Konishi H
Xenobiotica; 2018 Jan; 48(1):53-59. PubMed ID: 28051340
[TBL] [Abstract][Full Text] [Related]
7. Application of the PKCYP-test to predict the amount of in vivo CYP2C11 using tolbutamide as a probe.
Matsunaga N; Nishijima T; Hattori K; Iizasa H; Yamamoto K; Kizu J; Takanaka A; Morikawa A; Nakashima E
Biol Pharm Bull; 2001 Nov; 24(11):1305-10. PubMed ID: 11725969
[TBL] [Abstract][Full Text] [Related]
8. Effects of vitexin on the pharmacokinetics and mRNA expression of CYP isozymes in rats.
Wang XS; Hu XC; Chen GL; Yuan X; Yang RN; Liang S; Ren J; Sun JC; Kong GQ; Gao SG; Feng XS
Phytother Res; 2015 Mar; 29(3):366-72. PubMed ID: 25447838
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Rat CYP1A2 and CYP2C11 by Honokiol, a Component of Traditional Chinese Medicine.
Li J; Li MR; Sun B; Liu CM; Ren J; Zhi WQ; Zhang PY; Qiao HL; Gao N
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):787-796. PubMed ID: 31175627
[TBL] [Abstract][Full Text] [Related]
10. Characterization of recombinant CYP2C11: a vitamin D 25-hydroxylase and 24-hydroxylase.
Rahmaniyan M; Patrick K; Bell NH
Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E753-60. PubMed ID: 15585593
[TBL] [Abstract][Full Text] [Related]
11. Impact of Herbal Medicines like Nigella sativa, Trigonella foenum-graecum, and Ferula asafoetida, on Cytochrome P450 2C11 Gene Expression in Rat Liver.
Korashy HM; Al-Jenoobi FI; Raish M; Ahad A; Al-Mohizea AM; Alam MA; Alkharfy KM; Al-Suwayeh SA
Drug Res (Stuttg); 2015 Jul; 65(7):366-72. PubMed ID: 25099385
[TBL] [Abstract][Full Text] [Related]
12. Effects of
Ye H; Sui D; Liu W; Yuan Y; Ouyang Z; Wei Y
Xenobiotica; 2019 Dec; 49(12):1478-1484. PubMed ID: 30724651
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of imrecoxib on mRNA and protein expression of CYP2C11 enzyme in rats.
Wu X; An Q; Dong J; Wang K; Jin Y; Liu X; Zhang Z
Biomed Chromatogr; 2022 Oct; 36(10):e5439. PubMed ID: 35778888
[TBL] [Abstract][Full Text] [Related]
14. Exploring the biotransformation of N-(2-hydroxyphenyl)-2-propylpentanamide (an aryl valproic acid derivative) by CYP2C11, using in silico predictions and in vitro studies.
Mendieta-Wejebe JE; Silva-Trujillo A; Bello M; Mendoza-Figueroa HL; Galindo-Alvarez NL; Albores A; Tamay-Cach F; Rosales-Hernández MC; Romero-Castro A; Correa-Basurto J
J Pharm Pharmacol; 2020 Jul; 72(7):938-955. PubMed ID: 32307724
[TBL] [Abstract][Full Text] [Related]
15. Polysaccharide peptides from Coriolus versicolor competitively inhibit tolbutamide 4-hydroxylation in specific human CYP2C9 isoform and pooled human liver microsomes.
Yeung JH; Or PM
Phytomedicine; 2011 Oct; 18(13):1170-5. PubMed ID: 21757329
[TBL] [Abstract][Full Text] [Related]
16. Generation and Characterization of a CYP2C11-Null Rat Model by Using the CRISPR/Cas9 Method.
Wei Y; Yang L; Zhang X; Sui D; Wang C; Wang K; Shan M; Guo D; Wang H
Drug Metab Dispos; 2018 May; 46(5):525-531. PubMed ID: 29444903
[TBL] [Abstract][Full Text] [Related]
17. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based inactivation of CYP2C11 by diclofenac.
Masubuchi Y; Ose A; Horie T
Drug Metab Dispos; 2001 Sep; 29(9):1190-5. PubMed ID: 11502726
[TBL] [Abstract][Full Text] [Related]
19. Effect of antidepressant drugs on cytochrome P450 2C11 (CYP2C11) in rat liver.
Wójcikowski J; Haduch A; Daniel WA
Pharmacol Rep; 2013; 65(5):1247-55. PubMed ID: 24399720
[TBL] [Abstract][Full Text] [Related]
20. Interaction of drugs and Chinese herbs: pharmacokinetic changes of tolbutamide and diazepam caused by extract of Angelica dahurica.
Ishihara K; Kushida H; Yuzurihara M; Wakui Y; Yanagisawa T; Kamei H; Ohmori S; Kitada M
J Pharm Pharmacol; 2000 Aug; 52(8):1023-9. PubMed ID: 11007075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
